The role of soluble TNF receptors for TNF-α in uveitis

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 7, 2007, Pages 3246-3252

  Sugita, Sunao ^a   Takase, Hiroshi ^a   Taguchi, Chikako ^b   Mochizuki, Manabu ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

AQUEOUS HUMOR; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE INFLAMMATION; HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE; UVEITIS; CELL LINE; COCULTURE; DRUG EFFECT; FLOW CYTOMETRY; METABOLISM; VITREOUS BODY;

AQUEOUS HUMOR; CELL LINE; COCULTURE TECHNIQUES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RECOMBINANT PROTEINS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; UVEITIS; VITREOUS BODY;

EID: 34548103035     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.06-1444     Document Type: Article

References (43)

1. Dembic Z, Loetscher H, Gubler U, et al. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine. 1990;2:231-237.
2. Lens SM, de Jong R, Hooibrink B, et al. Phenotype and function of human B cells expressing CD70 (CD27 ligand). Eur J Immunol. 1996;26:2964-2971.
3. Clark LB, Foy TM, Noelle RJ. CD40 and its ligand. Adv Immunol. 1996;63:43-78.
4. Suda T, Takahashi T, Golstein P, et al. Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family. Cell. 1993;75:1169-1178.
5. Vilcek J, Lee TH. Tumor necrosis factor: new insights into the molecular mechanisms of its multiple actions. J Biol Chem. 1991;266:7313-7316.
6. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today. 1992;13:151-153.
7. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine: evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990;265:1531-1536.
8. Aderka D, Engelmann H, Shemer-Avni Y, et al. Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res. 1992;11:157-159.
9. Aderka D, Engelmann H, Maor Y, et al. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992;175:323-329.
10. Nussenblatt RB, Palestine AG, Chan CC, et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467-471.
11. Sagawa K, Mochizuki M, Masuoka K, et al. Immunopathological mechanisms of human T cell lymphotropic virus type 1 (HTLV-I) uveitis; detection of HTLV-I-infected T cells in the eye and their constitutive cytokine production. J Clin Invest. 1995;95:852-858.
12. Sagawa K, Itoh K, Sakaguchi M, et al. Production of IL-8 and the other cytokines by T cell clones established from the ocular fluid of patients with Behcet's disease. Ocular Immunol Inflamm. 1995;3:63-71.
13. + T cells from patients with Vogt-Koyanagi-Harada disease recognize human melanocyte antigens. Invest Ophthalmol Vis Sci. 2006;47:2547-2554.
14. Santos LM, Marcos MC, Gallardo GJM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251-255.
15. Sayinalp N, Ozcebe OI, Ozdemir O, et al. Cytokines in Behcet's disease. J Rheumatol. 1996;23:321-322.
16. Turan B, Gallati H, Erdi H, et al. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Behcet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol. 1997;24:128-132.
17. Torun N, Callizo J, Orlic N, et al. Serum cytokine receptor levels in noninfectious uveitis. Ophthalmic Res. 2005;37:112-116.
18. + T cells in the affected organs of sarcoidosis patients. Clin Exp Immunol. 1995;102:399-405.
19. Sakaguchi M, Sugita S, Sagawa K, et al. Cytokine production by T cells infiltrating in the eye of uveitis patients. Jpn J Ophthalmol. 1998;47:262-268.
20. Nakamura S, Yamakawa T, Sugita M, et al. The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci. 1994;35:3884-3889.
21. Sartani G, Silver PB, Rizzo LV, et al. Anti-tumor necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest Ophthalmol Vis Sci. 1996;37:2211-2218.
22. Sugita S, Streilein JW. Iris pigment epithelium expressing CD86 (B7-2) directly suppress T cell activation in vitro via binding to cytotoxic T lymphocyte-associated antigen 4. J Exp Med. 2003;198:161-171.
23. Sippy BD, Hofman FM, Wright AD, et al. Soluble tumor necrosis factor receptors are present in human vitreous and shed by retinal pigment epithelial cells. Exp Eye Res. 1996;63:311-317.
24. Limb GA, Hollifield RD, Webster L, et al. Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci. 2001;42:1586-1591.
25. Yoshida M, Takeuchi M, Streilein JW. Participation of pigment epithelium of iris and ciliary body in ocular immune privilege. 1. Inhibition of T-cell activation in vitro by direct cell-to-cell contact. Invest Ophthalmol Vis Sci. 2000;41:811-821.
26. Drescher KM, Whittum-Hudson JA. Modulation of immune-associated surface markers and cytokine production by murine retinal glial cells. J Neuroimmunol. 1996;64:71-81.
27. Gearing AJH, Beckett P, Christodoulou M, et al. Processing of tumor necrosis factor-a precursor by metalloproteinases. Nature. 1994;370:555-559.
28. McGeehan GM, Becherer JD, Bast RC Jr, et al. Regulation of tumor necrosis factor-α processing by a metalloproteinase inhibitor. Nature. 1994;370:558-564.
29. Di Girolamo N, Verma MJ, McCluskey PJ, et al. Increased matrix metalloproteinases in the aqueous humor of patients and experimental animals with uveitis. Curr Eye Res. 1996;15:1060-1068.
30. Taylor AW, Streilein JW, Cousins SW. Identification of alpha-melanocyte stimulating hormone as a potential immunosuppressive factor in aqueous humor. Curr Eye Res. 1992;11:1199-1205.
31. Taylor AW, Streilein JW, Cousins SW. Immunoreactive vasoactive intestinal peptide contributes to the immunosuppressive activity of aqueous humor. J Immunol. 1994;153:1080-1085.
32. Cousins SW, McCabe MM, Danielpour D, et al. Identification of transforming growth factor beta as an immunosuppressive factor in aqueous humor. Invest Ophthalmol Vis Sci. 1991;32:2201-2211.
33. Sugita S Taguchi C, Takase H, et al. Soluble Fas ligand and soluble Fas in ocular fluid of patients with uveitis. Br J Ophthalmol. 2000;84:1130-1134.
34. Zheng L, Fisher G, Miller RE, at al. Induction of apoptosis in mature T cells by tumor necrosis factor. Nature. 377;1995:348-351.
35. Sharon LE, de Sauvage FJ, et al. Decreased sensitivity to tumor-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice. Nature. 372;1994:560-563.
36. Brio BE, O'Rourke LM, Pan Y, et al. IL-1 and TNF receptor-deficient mice show decreased inflammation in an immune complex model of uveitis. Invest Ophthalmol Vis Sci. 1999;40:2583-2589.
37. Dick AD, Forrester JV, Liversidge J, et al. The role of tumor necrosis factor (TNF-alpha) in experimental autoimmune uveoretinitis (EAU). Prog Retin Eye Res. 2004;23:617-637.
38. Ferguson TA, Herndon JM, Dube P. The immune response and the eye: a role for TNF alpha in anterior chamber-associated immune deviation. Invest Ophthalmol Vis Sci. 1994;35:2643-2651.
39. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med. 2004;200:277-285.
40. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of Infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol. 2004;31:1362-1368.
41. Dick AD, Duncan L, Hale G, et al. Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis. J Autoimmun. 1998;11:255-264.
42. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α. Arthritis Rheum. 1993;36:1681-1690.
43. Van Dullemen HM, van Deventer SJ, Hommes DW, et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995;109:129-135.